Accelerating generic oral formulation development using biorelevant dissolution-permeation testing and mechanistic in-silico modelling

With high-value oral medicines approaching patent expiry, generic drug developers need faster, more predictive approaches to formulation development. This webinar explores how biorelevant dissolution-permeation testing combined with mechanistic in-silico modelling can provide greater insight into drug absorption and formulation performance.

Learn how these complementary approaches can support more informed formulation decisions, accelerate development, and help reduce risk before costly clinical bioequivalence studies.

‍